Citation metrics β two divergent profiles. Semantic Scholar lists Felix Kohle with h-index 2, 8 total citations, and 7 papers β an evidently under-indexed record given his publication dates span 2017β2026 . OpenAlex records 65 works, 240 citations, h-index 10, and steep recent growth: 23 works and ~70 citations in 2026 alone, with topics concentrated in Medicine, Neuritis, Multiple Sclerosis, and Immunology . The database divergence itself is a known reliability caveat: neither source is exhaustive, and conclusions about early-career authors are inherently provisional.
Core scientific program: translational autoimmune neuropathy. Kohle's first-author narrative review on repurposing MS immunotherapies for CIDP (227 references, 17 citations) systematically maps B-cell depletion, complement inhibition, BTK inhibitors, cladribine, and FcRn inhibitors, while explicitly cautioning against over-generalization from negative trials (e.g., fingolimod in FORCIDP) and heterogeneous, uncontrolled cohorts . Notably, he reports no competing interests on that paper, though co-authors have industry relationships β a point of transparency worth crediting.
Preclinical rigor. His 2026 ActIIR-antibody study in EAN (31 female Lewis rats, randomized, blinded, dose-finding plus pooled replication) showed improved neuritis-score AUC, grip strength reverted to baseline, partial MNCV rescue, improved gait kinematics, preserved muscle fiber cross-sectional area, and reduced Atrogin-1/MuRF1 β while honestly reporting null CMAP differences and unchanged nerve inflammation/myelination . The author-reported limitations β only female rats, no ultrastructural axonal morphometry, absent myogenic differentiation markers β show commendable self-critical practice. An earlier first-author study of kinesin-5 inhibition in EAN (66 references, 14 citations) established his mechanistic regeneration focus .
Clinical and biomarker work. His most-cited contribution is the multicenter PROSA seizure registry in Annals of Intensive Care (39 citations), plus a 9-center German CIDP care-quality study, a CSF biomarker comparison study, and serum neurofilament light-chain work for CIDP diagnosis .
Strengths and blindspots. Strengths: methodological range (clinical scores, electrophysiology, DeepLabCut/AutoGaitA kinematics, LC-MS/MS proteomics, qPCR), transparent null-result reporting, DFG and Cologne Clinician Scientist Program funding, and collaborative networks spanning Cologne, DΓΌsseldorf, Essen, Berlin, and Bochum. Blindspots: small per-group rodent samples (n=4β12), single-sex cohorts, limited independent replication, German-language case reports with one erratum, and no PI-led clinical trials yet. Overall verdict: a competent, rapidly accelerating junior researcher whose potential likely exceeds current metrics, but who has not yet demonstrated independent scientific leadership at scale.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.